Actas urologicas espanolas最新文献

{"title":"Recommendations for the prevention and treatment of adverse effects of intravesical BCG","authors":"J.L. Alvarez-Ossorio,&nbsp;M. Alvarez-Maestro,&nbsp;J.M. Cozar-Olmo,&nbsp;M. Espinosa-Bosch,&nbsp;I. Florido-Pérez,&nbsp;F. Guerrero-Ramos,&nbsp;L. Martinez-Piñeiro,&nbsp;J. Olivares-Corral,&nbsp;M. Rodriguez-Quecedo,&nbsp;O. Rodriguez-Faba","doi":"10.1016/j.acuroe.2026.502005","DOIUrl":"10.1016/j.acuroe.2026.502005","url":null,"abstract":"<div><div>Intravesical Calmette-Guérin bacillus (BCG) instillation is the treatment of choice after transurethral resection of intermediate- and high-risk non-muscle-invasive bladder tumors (NMIBT). However, adverse effects (AEs) of BCG are common and can compromise adherence to treatment. Therefore, a group of experts in urology, hospital pharmacy and nursing reviewed the most recent literature and developed a series of practical recommendations for the prevention, early detection, and treatment of adverse events (AEs) associated with BCG vaccination. These include a questionnaire for AE detection, the treatment of the most common local and systemic AEs, and precautionary recommendations, ranging from BCG preparation to excreta management. Special attention has been given to a multidisciplinary and coordinated approach between urologists, hospital pharmacists and nurses to optimize treatment adherence.</div></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"50 8","pages":"Article 502005"},"PeriodicalIF":0.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148407632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of mirabegron for the treatment of bladder dysfunction in the pediatric population: A prospective observational study","authors":"L.E. Zelaya-Contreras,&nbsp;M. Ruiz-Medina,&nbsp;V. Vargas Cruz,&nbsp;R.M. Paredes Estebán,&nbsp;A. Parente Hernández","doi":"10.1016/j.acuroe.2026.502000","DOIUrl":"10.1016/j.acuroe.2026.502000","url":null,"abstract":"<div><h3>Introducction</h3><div>Standard treatments for paediatric lower urinary tract dysfunction, including anticholinergics and intravesical botulinum toxin, may be limited by adverse effects and suboptimal response. Mirabegron, a β3-adrenergic receptor agonist, offers an alternative mechanism of action; however, paediatric evidence remains limited. This study aimed to evaluate its safety and clinical efficacy.</div></div><div><h3>Materials and methods</h3><div>A prospective observational study included patients treated with mirabegron between November 2023 and November 2024, with follow-up until November 2025. Mirabegron was used as second- or third-line therapy. Clinical response was assessed based on changes in urinary symptoms (frequency, urgency, nocturnal enuresis, and daytime urinary incontinence) and categorised as complete improvement (resolution), partial improvement (reduction), or no change. Adverse events were recorded. In a subgroup, urodynamic parameters were assessed before and after treatment.</div></div><div><h3>Results</h3><div>Fifteen patients were included (mean age 12 years), with a mean treatment duration of 12 months. Clinical improvement was observed in 78% of patients. Paired urodynamic studies were available in seven patients, showing significant improvements in maximum cystometric capacity, bladder compliance, and detrusor pressure during filling. Two patients experienced mild adverse events. One patient discontinued treatment due to difficulty swallowing the tablet. No clinically relevant cardiovascular changes were observed.</div></div><div><h3>Conclusions</h3><div>Mirabegron demonstrated a favourable safety profile and was associated with clinically meaningful improvement in symptoms and urodynamic parameters, supporting its use in selected paediatric patients with lower urinary tract dysfunction.</div></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"50 8","pages":"Article 502000"},"PeriodicalIF":0.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148407637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Morphometric changes in pelvic floor structure following non-invasive rehabilitation and neuromodulation assessed by ultrasound imaging","authors":"S. Maiti Bera,&nbsp;P. Palma,&nbsp;J.M. Santos Flores,&nbsp;E.P. Rodríguez Vidales","doi":"10.1016/j.acuroe.2026.501998","DOIUrl":"10.1016/j.acuroe.2026.501998","url":null,"abstract":"<div><h3>Introduction and objective</h3><div>Pelvic floor disorders represent a common problem in female urology practice and significantly affect quality of life. Objective evidence regarding structural changes induced by non-invasive neuromodulation remains limited. The aim of this study was to evaluate, using pelvic floor ultrasound (PFUS), the morphometric changes occurring in the pelvic floor following neuromodulation with high intensity focused electromagnetic energy (HIFEM).</div></div><div><h3>Materials and methods</h3><div>This was an analytical, quasi-experimental, prospective observational study with pre- and post-intervention assessment. The study included women with pelvic floor dysfunction treated with transperineal neuromodulation using HIFEM. Urinary symptoms, quality of life, and morphometric parameters were assessed using PFUS.</div></div><div><h3>Results</h3><div>Forty-six women with a mean age of 60.4 ± 12.6 years were analyzed. Significant improvements were observed in urinary frequency, ICIQ-SF, ICIQ-OAB, Sandvik Severity Index, and King’s Health Questionnaire scores (<em>p</em> &lt; 0.001). Ultrasound findings demonstrated reduced detrusor thickness, improved bladder emptying, enhanced pelvic floor dynamic activity, and improved pelvic support.</div></div><div><h3>Conclusions</h3><div>HIFEM neuromodulation was associated with improvements in clinical outcomes and quality of life, as well as morphometric changes in the pelvic floor objectively demonstrated by transperineal ultrasound.</div></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"50 8","pages":"Article 501998"},"PeriodicalIF":0.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148213846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of intravesical BCG Therapy on quality of life in non–muscle-invasive bladder cancer: a prospective evaluation using the FACT-Bl questionnaire","authors":"J. Caño-Velasco,&nbsp;A. Luis-Cardo,&nbsp;J.C. Moreno-Cortés,&nbsp;L. Carrasco-Loras,&nbsp;J. Astudillo-Campoverde,&nbsp;J.D. Subiela,&nbsp;F. Lozano-Palacio,&nbsp;M. Campistol-Torres,&nbsp;R. Pichler,&nbsp;A. Partl,&nbsp;F. Lackner,&nbsp;F. Del Giudice,&nbsp;D. Carino,&nbsp;L.A. García-Martín,&nbsp;P. Salamanca-Blanco,&nbsp;A. Bielsa-Carrillo,&nbsp;A.M. Pastor-Cordero,&nbsp;V. Bataller-Monfort,&nbsp;A. Tello-Delsors,&nbsp;L. Polanco-Pujol,&nbsp;C. Hernández-Fernández","doi":"10.1016/j.acuroe.2026.501937","DOIUrl":"10.1016/j.acuroe.2026.501937","url":null,"abstract":"<div><h3>Introduction and objective</h3><div>Intravesical bacillus Calmette-Guérin(BCG) remains the standard treatment for high-risk non-muscle-invasive bladder cancer(NMIBC) and is also considered an option for intermediate and very high-risk groups. Despite over five decades of clinical use, limited information is available regarding patients’ quality of life(QoL) during therapy. The objective was to evaluate QoL patients receiving BCG therapy using the Functional Assessment of Cancer Therapy-Bladder Cancer(FACT-Bl) questionnaire.</div></div><div><h3>Materials and methods</h3><div>Prospective multicentre observational study from February 2022 to June 2024 in patients with NMIBC. Patients completed the FACT-Bl questionnaire before and after the induction course. The results of both questionnaires were compared with Student's t-test for paired data using IBM®SPSS-Statistics-25.</div></div><div><h3>Results</h3><div>A total of 235 patients completed both questionnaires and were analysed. 97% of the series completed BCG induction. A worsening in the physical well-being(PWB) subscale(P &lt; 0.05) and an improvement in the emotional well-being(EWB) subscale(P &lt; 0.05) were observed in the total series of cases, without differences in total scores. In BCG-naive patients (90%), significant deterioration was observed in PWB subscale(P &lt; 0.05) and FACT-Bl Trial Outcome Index(TOI) (P &lt; 0.05). Patients over 75 years showed a statistically significant improvement in EWB, while those aged ≤75 years experienced significant declines in PWB, bladder cancer subscale (BlCS), and three total scores. Limitations include exclusive use of FACT-Bl questionnaire to assess QoL and limited sample size.</div></div><div><h3>Conclusions</h3><div>BCG induction therapy shows no significant impact on overall FACT-Bl scores but declines PWB and improves EWB subscales. Age and prior BCG exposure influence outcomes; notably, patients aged ≤75 show marked declines in PWB, BlCS and total FACT-Bl scores.</div></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"50 8","pages":"Article 501937"},"PeriodicalIF":0.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147483021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functional outcomes of a biofeedback-guided pelvic floor muscle training program following robot-assisted radical prostatectomy","authors":"I. Millán-Ramos,&nbsp;A. Zambudio-Munuera,&nbsp;A. Donaire-Barrera,&nbsp;P. Rodríguez-Parras,&nbsp;M.I. Martinez-Sanchez,&nbsp;M. Arrabal-Martín,&nbsp;M.A. Arrabal-Polo","doi":"10.1016/j.acuroe.2026.501999","DOIUrl":"10.1016/j.acuroe.2026.501999","url":null,"abstract":"<div><h3>Objective</h3><div>Urinary incontinence remains one of the main functional sequelae after robot-assisted radical prostatectomy (RARP). This study aimed to evaluate urinary continence and functional outcomes in patients enrolled in a structured postoperative pelvic floor muscle training program with biofeedback.</div></div><div><h3>Methods</h3><div>We conducted a single-centre retrospective observational study including consecutive patients who underwent RARP between November 2024 and October 2025 and entered a postoperative biofeedback-guided pelvic floor rehabilitation program, with a minimum follow-up of 3 months. Patients with previous pelvic radiotherapy, preoperative urinary incontinence or incomplete key data were excluded. Biofeedback was started 12–14 days after hospital discharge, coinciding with catheter removal, and included 3–4 supervised sessions according to clinical progress, together with a home exercise program. The primary outcome was urinary continence, defined as the use of 0–1 pad/day, at 3 and 6 months after surgery.</div></div><div><h3>Results</h3><div>Ninety patients were included. Mean age was 64.4 ± 6.3 years and mean body mass index was 29.1 ± 4.3 kg/m². Continence rates were 88.9% at 3 months and 94.4% at 6 months. Lower 24-h pad test values were significantly associated with continence at the first and second follow-up visits (both <em>p</em> &lt; 0.001). No significant associations were found between 3-month continence and age, body mass index, preoperative PSA, prostate volume or catheterisation time. Nevertheless, the number of biofeedback sessions was significantly associated with continence recovery, suggesting a possible dose-response effect.</div></div><div><h3>Conclusions</h3><div>A structured postoperative pelvic floor rehabilitation program with biofeedback was associated with high rates of early continence recovery after RARP. The intensity of supervised rehabilitation may influence functional recovery. Prospective controlled studies are warranted to confirm these findings.</div></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"50 8","pages":"Article 501999"},"PeriodicalIF":0.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148427905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The future of actas urológicas Españolas: one scientific journal, one identity, and an international outlook","authors":"Óscar Rodríguez Faba","doi":"10.1016/j.acuroe.2026.502073","DOIUrl":"10.1016/j.acuroe.2026.502073","url":null,"abstract":"","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"50 8","pages":"Article 502073"},"PeriodicalIF":0.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148892841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expected versus experienced pain in office-based flexible cystoscopy: A prospective study","authors":"A. Golbasi,&nbsp;E. Kızılay,&nbsp;A.Y. Ozercan,&nbsp;B. Elmaagac,&nbsp;H. Bicer,&nbsp;S. Tozan,&nbsp;M.A. Karadag","doi":"10.1016/j.acuroe.2026.502032","DOIUrl":"10.1016/j.acuroe.2026.502032","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>This study prospectively evaluated the relationship between pre-procedural pain expectations and experienced pain during first-time office-based cystoscopy, and assessed whether the discrepancy between them is influenced by age and gender in an outpatient tertiary care setting.</div></div><div><h3>Materials and methods</h3><div>This prospective study included adults undergoing first-time office-based cystoscopy between January and April 2026, excluding those with prior cystoscopy or chronic pain requiring analgesics/anxiolytics. All procedures were performed by a single urologist using a 16-Fr flexible cystoscope with intraurethral lidocaine. Expected and experienced pain were assessed using a 0–10 numerical rating scale and analyzed by age and gender, with p &lt; 0.05 considered significant.</div></div><div><h3>Results</h3><div>A total of 117 patients (83 males, 34 females; mean age 57.6 ± 11.7 years) were included. Post-procedural pain scores were significantly lower than pre-procedural expectations in both male and female patients (all p &lt; 0.001). The magnitude of pain reduction did not differ significantly between male and female patients (p = 0.114) or between patients aged &lt;65 and ≥65 years (p = 0.573). Overall, median pain scores decreased from 6 (5–7) before the procedure to 2 (2–4) after the procedure. Procedure duration was 1.54 ± 0.3 min and did not differ by sex or age. The majority of patients (81.2%) would undergo repeat cystoscopy if required, with no significant difference between male and female patients.</div></div><div><h3>Conclusions</h3><div>Patients undergoing office-based cystoscopy report significantly lower pain than anticipated, and these findings may inform clinical counseling by facilitating reassurance and contributing to reduced anxiety through effective pre-procedural education.</div></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"50 8","pages":"Article 502032"},"PeriodicalIF":0.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148537971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BCG and systemic immunotherapy for high-risk non-muscle-invasive bladder cancer: Lights and shadows","authors":"F. Guerrero-Ramos","doi":"10.1016/j.acuroe.2026.501936","DOIUrl":"10.1016/j.acuroe.2026.501936","url":null,"abstract":"","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"50 8","pages":"Article 501936"},"PeriodicalIF":0.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147313940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative outcomes of Mini-PCNL and suction-assisted flexible ureteroscopy in patients with renal stones ≥2 cm","authors":"Hüseyin Mert Durak,&nbsp;Adem Sancı,&nbsp;Emre Hepşen,&nbsp;Orçun Burak Karadağ,&nbsp;Metin Yığman,&nbsp;Kubilay Sarıkaya,&nbsp;Azmi Levent Sağnak","doi":"10.1016/j.acuroe.2026.501997","DOIUrl":"10.1016/j.acuroe.2026.501997","url":null,"abstract":"<div><h3>Introduction</h3><div>To compare the efficacy and perioperative outcomes of miniaturized percutaneous nephrolithotomy (mini-PCNL) and flexible ureteroscopy with flexible and navigable suction ureteral access sheath (FANS-UAS) in the management of renal stones larger than 2 cm.</div></div><div><h3>Material and method</h3><div>This retrospective comparative study evaluated 252 adults with renal stones ≥2 cm treated between May 2024 and December 2025. Mini-PCNL was performed in 142 patients and FANS-UAS–assisted flexible ureteroscopy in 110. Preoperative non-contrast CT was used to characterize stones, and postoperative CT determined stone-free status as the primary endpoint. Operative time, hemoglobin drop, length of stay, Clavien–Dindo complications, and auxiliary intervention rates were analyzed as secondary outcomes.</div></div><div><h3>Results</h3><div>Stone-free rates did not differ significantly between mini-PCNL and FANS-UAS–assisted flexible ureteroscopy (83.1% vs. 76.4%, <em>p</em> = 0.242). Mini-PCNL provided shorter operative times but resulted in greater hemoglobin decline, longer hospitalization, and more minor complications, while major complications were similar. Although mini-PCNL yielded higher stone-free rates in lower pole stones, this was not statistically significant. FANS-UAS was more frequently applied in older, comorbid patients and maintained satisfactory efficacy with a favorable perioperative profile.</div></div><div><h3>Conclusions</h3><div>Both mini-PCNL and FANS-UAS–assisted flexible ureteroscopy achieved effective stone clearance for renal stones &gt;2 cm. Mini-PCNL was faster, whereas FANS-UAS was associated with lower perioperative morbidity, despite lower adjusted odds of stone-free status compared with mini-PCNL. These results support an individualized approach to procedure selection in large renal stones, with stone burden, lower pole involvement, and patient comorbidity considered together in treatment planning.</div></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"50 8","pages":"Article 501997"},"PeriodicalIF":0.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148213801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reconstructing the reconstructed: Outcomes of redo-urethroplasty for recurrent urethral strictures","authors":"R. Uğur,&nbsp;E.T. Keskin,&nbsp;M. Savun,&nbsp;E. Aktaş,&nbsp;A. Şimşek","doi":"10.1016/j.acuroe.2026.501996","DOIUrl":"10.1016/j.acuroe.2026.501996","url":null,"abstract":"<div><h3>Introduction</h3><div>In this study, we aimed to evaluate the results of redo-urethroplasty and to determine the risk factors contributing to the recurrence of stricture.</div></div><div><h3>Methods</h3><div>Male patients with a history of urethroplasty who underwent redo-urethroplasty were retrospectively evaluated and included in the study. Classifications were made according to patient characteristics, features of the stricture, and the surgical procedure performed. Success criteria was defined as anatomical success, which was determined by the resistance-free passage of a 16-Fr flexible cystoscope through the reconstructed urethral lumen. After identifying the influencing factors, univariate and multivariable logistic regression analyses were conducted to determine the predictors for recurrence.</div></div><div><h3>Results</h3><div>A total of 396 male patients who underwent urethroplasty were evaluated, with 76 patients meeting the established criteria for inclusion. The mean age was 42.3 (10−81) years, and the average follow-up period was 44 (13–78) months. The majority of patients (54%) had bulbar strictures, and the average stricture length was 4.8 ± 2.4 (1.3–12) cm. Treatment success was achieved in 72.4% of patients. In univariate analyses, factors statistically significantly (<em>P</em> &lt; .05) associated with recurrence included smoking, diabetes mellitus, stricture length, etiology, and the presence of complications. In the multivariable logistic regression analysis, presence of complications remained statistically significant (<em>P</em> &lt; .05) as an independent predictor of recurrence.</div></div><div><h3>Conclusions</h3><div>Smoking, diabetes mellitus, stricture length, etiology, and postoperative complications were significantly associated with stricture recurrence. These results suggest that patient-related, stricture-related, and perioperative factors influence recurrence risk after redo-urethroplasty.</div></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"50 8","pages":"Article 501996"},"PeriodicalIF":0.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148038769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}